Press

Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor

Dec 14 • 3 min read

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being is pleased to announce that it has closed the second tranche of its previously announced private placement of up to CAD$3 million. The Company has issued 7,751,859 common shares at a price of…

Small Pharma To Support University College London Research Project on Neuroplasticity

Dec 14 • 2 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it will provide its drug candidate SPL026, an intravenous formulation of the psychedelic drug N, N-dimethyltryptamine, to support a University College London led study investigating induced brain changes and neuroplasticity following intravenous…

Palo Alto IV Ketamine Depression Therapy Launched By Soft Reboot Wellness

Dec 14 • 3 min read

Soft Reboot Wellness’ expanded ketamine therapy is offered in response to growing calls for more effective approaches to major depressive disorder. Led by board-certified anesthesiologist Dr. Sara Herman MD, Soft Reboot Wellness utilizes the scientific basis behind ketamine’s promise as a tool or catalyst to help heal from depression. More details can be found at https://www.softrebootwellness.com/how-does-ketamine-help-where-antidepressants-dont…

Tryp Therapeutics Announces Fiscal Year 2022 Financial Results and Reports Corporate Highlights

Dec 14 • 4 min read

Tryp Therapeutics, Inc. (CSE: TRYP | OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today reported on corporate highlights from 2022 and announced the filing of its audited financial statements for the fiscal year ending August 31, 2022. Complete financial statements along with…

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100

Dec 13 • 3 min read

Clearmind Medicine Inc. (Nasdaq, CSE: CMND | FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under treated health problems, today announced it has completed IND-enabling studies on its CMND-100 (MEAI- based) compound aimed at treating alcohol use disorder (AUD), in preparation for its first in-human clinical…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435